This is the authors' abstract. We don't add key points for this paper.
Tamoxifen behaves as an estrogen agonist in breast cancer cells that express high levels of AIB1 and HER2, resulting in de novo resistance. Gefitinib's ability to eliminate this cross-talk and to restore tamoxifen's antitumor effects should be tested in the clinic.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shou et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: